Notícias e Atualizações de Avalyn
Voltar ao PerfilReceba as últimas notícias, atualizações e conteúdo sobre Avalyn. Não perca nenhuma fofoca ou novo conteúdo adulto dela.
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves
Why Avalyn Pharma is on investors’ radar Avalyn Pharma (AVLN) has drawn attention after recent sha...
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PP...
Avalyn to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biophar...
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for ...
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biophar...
Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline
Avalyn Pharma Inc. (AVLN) has filed to raise capital for its treatment pipeline development, accordi...
Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...
Avalyn Pharma Inc AVLN
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies...
Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials
The lung disease idiopathic pulmonary fibrosis (IPF) has few available treatments, and that medical ...
Avalyn Pharma raises $300M in IPO, shares surge 64% on first day of trading
To continue reading this content, please enable JavaScript in your browser settings and refresh this...
Avalyn Announces Pricing of Upsized Initial Public Offering
BOSTON, April 29, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc. (Nasdaq: AVLN) ("Avalyn”), a clinical...
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Avalyn Pharma on Wednesday raised $300 million in a large initial public offering that’ll support ...
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Avalyn Pharma Inc. (Nasdaq: AVLN) (Avalyn or the Company), a clinical-stage biopharmaceutical compan...
Inhaled drug developer Avalyn files for U.S. IPO
Avalyn Pharma (AVLN), a biotech focused on developing inhaled therapeutics for the lung disorder pul...
Avalyn Pharma outlines inhaled fibrosis push after IPO, with pivotal data ahead
Avalyn Pharma (NASDAQ:AVLN) executives outlined the company's inhaled pulmonary fibrosis strategy at...
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmac...
Avalyn Pharma Inc
View Avalyn Pharma Inc AVLN stock quote prices, financial information, real-time forecasts, and comp...
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...
Lung disease drug developer Avalyn surges on public debut
Avalyn Pharma (AVLN), a biotech focused on developing inhaled therapeutics for the lung disorder pul...
Avalyn Pharma Sets IPO at 16.7 Million Shares Priced at $16-$18 Each
Avalyn Pharma on Wednesday plans to sell nearly 16.7 million shares at between $16 and $18 apiece in...
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled the...
Avalyn: Q1 Earnings Snapshot
Avalyn Pharma Inc. (AVLN) on Wednesday reported a loss of $26.9 million in its first quarter....
Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury
BOSTON, April 27, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc., a clinical-stage biopharmaceutical com...
Keyword: avalyn hunter
Kingmambo excelled at a mile on the track but his offspring have shown a mix of speed and stamina. H...
Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fun...
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceu...
Avalyn Pharma Surges 44% After $300 Million Upsized IPO
Avalyn opened at $26, above its $18 IPO price, giving the rare lung disease biotech a market value o...
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled the...
Avalyn Pharma Upsized IPO Priced at Top of Expectations
Shares of Avalyn Pharma are set to make their trading debut Thursday after the clinical-stage biopha...
Avalyn seeks $300m from its IPO
Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscale...
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
CAMBRIDGE, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...